Thubrikar Aortic Valve, Inc.

Our next-gen Transcatheter Aortic Valve Implantation (TAVI) system was designed for durability. It's shown preclinical superiority, and clinical feasibility.

  • Stage Prototype Ready
  • Industry Medical Devices and Equipment
  • Location Norristown, PA, USA
  • Currency USD
  • Founded October 2010
  • Employees 4
  • Incorporation Type C-corp
  • Website

Company Summary

Dr. Mano Thubrikar designed the Optimum Transcatheter Aortic Valve Implantation (TAVI) for maximum valve durability and precise delivery. We completed a FIH study in Europe in 2022, and all 5 patients are doing very well. In 2018, our first patient was implanted in Brazil, and is also doing very well. Preclinical superiority shown (e.g. 24 years in durability test, less pressure gradient in sheep).


  • President, Founder, and Board Director

    Dr. Thubrikar is a world-renowned authority on the aortic valve. He previously worked as Director of BME at South Dakota School of Mines and Technology; as Edwards Distinguished Research Scientist at Edwards Lifesciences Corp.; as Director of BME at The Heineman Medical Research Center; and as Director of Surgical Research in the Department of Surgery at UVA. Dr. Thubrikar authored “Vascular Mechanics and Pathology” and “The Aortic Valve”.

  • Co-Founder, Counsel and Corporate Secretary

    Mr. Heble is a registered patent attorney with significant experience handling intellectual property matters related to a wide range of life science-based technologies. Mr. Heble began his legal career with an Am Law 100 law firm, and most recently held the position of Senior Patent Counsel for a Fortune 500 consumer products company.

  • Co-Founder, Vice President of Business Development

    Mr. Wadke leads the strategic operations of the Company with over 20+ years of cross-functional experience. Prior to the Company, he consulted for early-stage pharmaceutical companies. From 2007-2009, he worked for VGX Pharma in Business Development, including its integration of an acquisition and its merger with Inovio BioMedical (NYSEMKT:INO). He previously worked in financial, marketing, and strategy roles at J.P. Morgan and MB Financial.

  • Board Director, Principal Investor

    Mr. Parate has over 20 years of entrepreneurial and management experience in the financial industry. He began his career at Susquehanna International Group, and has since co-founded multiple trading firms. He consults part-time for the Company.


Previous Investors

Starting a startup?

Join the world's largest startup network for guidance, tools, and fundraising opportunities.

Get Started for Free